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Abstract
Antimicrobial shortages have made treating certain infections more difficult. A webbased survey 
asking about experience with antimicrobial drug shortages was distributed in 2011 to 1328 
infectious diseases physician members of the Emerging Infectious Diseases Network of the 
Infectious Diseases Society of America. A majority (78%) of 627 respondents reported needing to 
modify antimicrobial choices because of drug shortages within the past 2 years. Antimicrobials 
most often reported as not available or available but in short supply were: trimethoprim-
sulfamethoxazole injection (by 65% of respondents), amikacin (by 58%), aztreonam (by 31%), 
and foscarnet (by 22%). Most respondents (55%) reporting a shortage indicated that the shortage 
adversely affected patient outcomes and that they were forced to use alternative and second line 
agents which were either less effective, more toxic or more costly. Most (70%) indicated that they 
learned about the shortage from contact with the pharmacy after trying to prescribe a drug in short 
supply. More effective means of informing physicians about drug shortages is critical to lessen the 
impact on patient care.
Introduction
The shortage of prescription medications has the potential to cause significant morbidity and 
mortality (Jensen and Rappaport, 2010, Steinbrook, 2009). Shortages of antimicrobial agents 
are of particular concern and have been characterized as a public health emergency (Griffith 
et al, 2012a) due to the need to start these agents promptly and also because rising 
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antimicrobial resistance rates limit therapeutic options for an increasing number of 
pathogens (Pulcini et al, 2012). Furthermore, for lack of financial and other incentives, there 
is a shortage of new antimicrobial agents in the pharmaceutical industry pipeline (Freire-
Moran et al, 2011, Spellberg et al, 2011).
Shortages of antimicrobials are reported by the Food and Drug Administration (FDA) (US 
Food and Drug Administration, 2012) and professional organizations such as the American 
Society of Health System Pharmacists (ASHP) (American Society of Health-Systems 
Pharmacists, 2012). Although the direct impact of shortages is not easy to measure, the 
effects on individual patients and public health are considered significant (Hampton, 2007, 
Harbarth et al, 2003, Pluss-Suard et al, 2012, Steinbrook, 2009). Recent surveys of 
pharmacists have documented shortages of medications including antimicrobial agents in the 
US (American Society of Health-Systems Pharmacists, 2011), Canada (Canadian 
Pharmacists Association, 2010) and Europe (The ESCMID Study Group for Antibiotic 
Policies ESGAP, 2007). Recently, an analysis and review of recent anti-infective drug 
shortages from the web site of the AHSP addressed a list of shortages, reasons and time 
periods (Griffith et al, 2012a). A survey directed exclusively at infectious diseases (ID) 
physicians was performed a decade ago (Sparling, 2001, Strausbaugh et al, 2001). To 
capture recent experiences and perspectives of practicing ID physicians on antimicrobial 
agent shortages, we report results of a 2011 web-based survey that was sent to all registered 
members of the Infectious Diseases Society of America.
Materials and Methods
A nine-question survey web link was sent by email in May 2011 to all 1328 physician 
members of the Infectious Diseases Society of America’s Emerging Infections Network 
(IDSA EIN) from the U.S and Puerto Rico. Two reminders were sent to non-responders in 
the monthlong open period. The EIN is a sentinel network of ID physicians who regularly 
engage in clinical activity and who volunteer to participate. The network has been funded by 
the Centers for Disease Control and Prevention (CDC) since 1995 and has been known to be 
in the forefront of important clinical ID issues (Infectious Diseases Society of America, 
2011).
The physicians were asked for their experiences regarding need for modifying management 
of an infectious disease due to a shortage, availability of antimicrobial agents in their 
practices within the past 2 years, whether they had encountered any adverse events as a 
result of shortages, and how they learned of the shortage. Descriptive statistics were used to 
analyze survey responses.
Results
A total of 627 (47%) of the 1328 active members of the EIN responded. The respondents 
were from all U.S. Bureau of Census divisions and Puerto Rico. Nearly equal proportions of 
respondents declared their primary place of practice to be either hospital or clinic, private or 
group practice, university or medical school, and the US Department of Veterans Affairs 
facilities (VA) or the military.
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Seventy eight percent of the respondents indicated a need to modify their antimicrobial 
choice for treating or preventing an infectious disease because of a drug shortage within the 
past 2 years. Physicians in the East North Central U.S. Bureau of Census division reported 
the highest rate (83%) of shortages and the New England region, the lowest (62%, p= 
0.2771). Reported shortages also varied by the type of hospital: ID physicians working in 
non-university teaching hospitals (82%) and community hospitals (80%) reported shortages 
significantly more often than those working in the VA or the military (70%, p=0.046). 
Reported shortages did not vary by hospital size.
Of the medications that were either not available or available but in short supply in the past 2 
years, the top 5 were all injectables: trimethoprim/sulfamethoxazole (TMP/SMX), amikacin, 
aztreonam, foscarnet sodium, and intravenous immune globulin (IVIG) (Table 1). Prominent 
oral medications reported in shortage included oseltamivir oral suspension and acyclovir 
tablets. Live zoster vaccine, yellow fever vaccine, and inactivated influenza vaccine were 
also reported to be in short supply.
Of the 490 respondents who reported a shortage, 253 (52%) expressed an opinion that the 
resulting change in treatment due to the shortage had adversely affected patient care or 
outcomes. Of the 253 respondents who reported adverse effects, the most common concerns 
were use of more toxic antimicrobials (62%), more expensive agents (41%), broader-
spectrum antimicrobials (38%), long-term morbidity from inadequate treatment of infection 
(28%) and longer hospitalizations (26%). Use of suboptimal, less-effective or more toxic 
therapy was the most commonly mentioned additional adverse outcome in an open-text field 
(7%). Specific examples included use of oral TMP/SMX or pentamidine for Pneumocystis 
jiroveci pneumonia instead of intravenous TMP/SMX, and increased use of colistin for 
multidrug-resistant Gramnegative bacilli in place of amikacin. Physicians also reported 5 
deaths attributed directly to antimicrobial agent shortages. No further information regarding 
these deaths was provided by the respondents.
A majority of the respondents (70%) indicated that they had learned of the shortage from 
their pharmacy only after prescribing the drug in short supply. Other common modes of 
learning about the shortage were from a colleague (59%), and from the FDA or ASHP 
websites (24%). A majority (70%) indicated that they had never visited the FDA shortages 
website. Fifty four percent indicated that they were not notified once the shortage was 
resolved. Suggestions to improve overall communication about drug shortages focused on 
messages from federal agencies, professional associations such as the IDSA, from 
pharmaceutical companies, and from the respondents’ own institutions and pharmacies. The 
preferred mode of communication was electronic.
The 137 respondents who did not report experiencing an antimicrobial drug shortage within 
the past two years were from all 9 U.S. Bureau of Census regions and represented all levels 
of infectious diseases experience from fellows-in-training to those in practice for more than 
25 years. Respondents whose primary employment was with state or local government were 
somewhat more likely to report not experiencing a shortage (by 55%, p= 0.3212) as 
compared to military physicians (50%), federal government employees (33%), university or 
medical school faculty (25%), hospital/clinic-based physicians (19%) and those in private or 
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group practice (15%). This may reflect less time in providing direct patient care in those 
settings.
Discussion
We found that 78% of ID physician respondents had experienced an antimicrobial drug 
shortage within the past 2 years. The agents most often reported as not available or available 
but in short supply were: trimethoprim-sulfamethoxazole injection, amikacin, aztreonam and 
foscarnet. Thus, our results indicate that antimicrobial agent shortages are commonly noted 
in the US. Furthermore, almost half of respondents indicated that, in their opinion, the 
shortage adversely affected patient care most often by exposing patients to less effective, 
more toxic or costly medications. Disturbingly, most respondents learned about the shortage 
from their pharmacy when trying to prescribe that agent for a patient. These reports often 
came several hours after the prescription had been written, leading to delays in treatment 
even when an alternative agent was procured.
In the decade since the last EIN survey of ID physicians on the topic of antimicrobial 
shortages, much has remained the same: shortages continue to occur with only the specific 
agents changing (Strausbaugh et al., 2001). In 1999 and 2000, the top 5 agents noted to be in 
short supply were a different group of injectables: penicillin G, meropenem, ticarcillin +/− 
clavulanate, cephazolin and gentamicin. Similar percentages of respondents in both surveys 
reported a need to modify treatment regimens due to antimicrobial agent shortage(s) with 
similar categories of adverse outcomes including greater toxicity, greater expense, wider 
spectrum of alternative agent, and inadequate treatment of infection. One key difference is 
that current shortages appear to be no longer “unexpected” (Sparling, 2001). Another 
difference is that shortages are no longer limited to antimicrobials. In 2011, ID physicians 
expressed concern about the shortage of IVIG and several vaccines.
Our results suggest several approaches to help minimize problems arising from future 
shortages. First, more effective ways are needed to alert physicians to an impending or actual 
shortage. Notifications regarding these shortages need to be readily available without 
creating information overload for busy clinicians. Second, more information is needed about 
alternative agents when first-line agents are not available and the alternative agents are 
considered a ‘distant second’. This information needs to be easily accessible so that busy 
clinicians are not required to perform literature searches at the point of care after notification 
regarding a shortage from a pharmacy. Data from clinical trials would be ideal but even 
aggregating existing relevant experiential data from small and large healthcare systems in 
the form of guidelines would be helpful. Antimicrobial stewardship programs, with support 
from professional associations, can play a role collecting and disseminating information and 
improving messaging to other providers.(Griffith et al, 2012b, Griffith et al, 2012c). Finally, 
shortages are often localized and are reported by institutions in one area but not in others for 
unknown reasons. Thus, different approaches will be needed in different settings.
Limitations to this survey are the self-reported nature of the results. The nature and extent of 
adverse events, the frequency and experience with the use of second-line agents, effects on 
special populations such as immune-compromised patients and reports of deaths among 
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patients attributed to antimicrobial agent shortages merit further investigation. Since most 
prescribers find out about shortages when actually prescribing an antimicrobial agent, those 
respondents who prescribe some agents less commonly, such as foscarnet or amikacin, 
might not be aware of existing shortages. Also, members who had experienced a shortage 
may have been more likely to respond, thus introducing response bias.
This survey was not designed to elucidate reasons for the shortages. In general, shortages of 
medications occur due to a combination of factors along the supply chain; most often cited 
reasons include bulk and raw material availability, manufacturing and quality problems, 
delays and discontinuations, voluntary recalls, economics of manufacturing, shifts in clinical 
practice and unexpected increase in demand(American Society of Health-Systems 
Pharmacists, 2012, Griffith et al, 2012b, US Food and Drug Administration, 2012). The 
reasons leading to shortages of IVIG and vaccines may be different to those associated with 
antimicrobials. Hospitals and pharmacies manage shortages in different ways(American 
Society of Health-Systems Pharmacists, 2012, Kaakeh et al, 2011). Management usually 
occurs in three phases: identification and assessment phase, preparation and contingency. 
Strategies include conducting a shortage analysis to assess impact, stewardship of existing 
supplies and arranging collaborations with other local healthcare systems for sharing 
existing supplies. At the government level, the FDA is active in pursuing both prevention 
and response strategies (US Food and Drug Administration, 2011). These include working 
with manufacturers to review practices, exercising regulatory discretion and asking other 
manufacturers to increase production.
The majority of ID physicians reported shortages of antimicrobial and biologic agents. The 
Institute for Healthcare Improvement has labeled the shortage “a crisis that has real 
consequences” (Institutes for Healthcare Improvement, 2011). The U.S. Government 
Accountability Office (GAO) has recently conducted a study to better understand drug 
shortages and to identify the steps the FDA could take to better identify and resolve drug 
shortages (http://www.gao.gov/products/GAO-12-315T). The GAO report reinforced widely 
held views that drug shortages were increasing and that the FDA was constrained by its lack 
of authority to require manufacturers to report potential or current shortages. The report did 
conclude that the FDA was able to prevent the majority of shortages if they had advance 
knowledge of those shortages.
In our opinion, mechanisms for addressing shortages in other fields, e.g., organ sharing 
programs for scarce organs, could potentially inform efforts to alleviate effects of 
antimicrobial shortages. Intense lobbying efforts by various professional organizations 
combined with an increased awareness of shortages has led to the enactment of a new law 
that requires pharmaceutical manufacturers to inform the FDA of temporary and permanent 
shortages and also provides incentives for developing new antibiotics. (One Hundred 
Twelfth Congress of the United States Of America, 2012) Given the limited number of new 
antimicrobial agents in the pharmaceutical industry pipeline (Freire-Moran et al, 2011, 
Spellberg et al, 2011) and the likelihood that shortages will continue to occur, better and up-
to-date ways must be found to address this longstanding unmet need. In understanding and 
addressing shortages, our goals must be to better understand the human aspect of the 
Gundlapalli et al. Page 5
Diagn Microbiol Infect Dis. Author manuscript; available in PMC 2018 February 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
shortage in terms of adverse events and how this affects the care, outcomes and quality of 
life of our patients.
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Table 1
Antimicrobial agents, biologicals and vaccines and reported to be in short supply by infectious disease 
physicians, May 2011 (N=number of ID physicians reporting a shortage, %=percent of 627 respondents)
Not available
N (%)
Available but short supply
N (%)
TMP/SMX injection 198 (32) 209 (33)
Amikacin injection 120 (19) 242 (39)
Foscarnet sodium injection 66 (11) 72 (11)
Aztreonam injection 54 (9) 143 (23)
Cefotetan injection 50 (8) 34 (5)
Zoster vaccine live 39 (6) 64 (10)
Posaconazole 25 (4) 61 (10)
Penicillin G (aqueous or benzathine) 24 (4) 86 (14)
Erythromycin lactobionate injection 25 (4) 24 (4)
Acyclovir tablets and capsules 22 (4) 54 (9)
Oseltamivir oral suspension 19 (3) 77 (12)
Yellow fever vaccine 13 (2) 65 (10)
Intravenous Immune Globulin IVIG (Human) 12 (2) 105 (17)
Inactivated influenza vaccine 10 (2) 60 (10)
Not available
N (%)
Available but short supply
N (%)
TMP/SMX injection 198 (31) 210 (33)
Amikacin injection 120 (19) 242 (38)
Foscarnet sodium injection 66 (11) 72 (11)
Aztreonam injection 55 (9) 143 (23)
Cefotetan injection 50 (8) 34 (5)
Zoster vaccine live 39 (6) 64 (10)
Posaconazole 25 (4) 61 (9)
Penicillin G (aqueous or benzathine) 24 (4) 86 (13)
Erythromycin lactobionate injection 25 (4) 24 (4)
Acyclovir tablets and capsules 22 (3) 54 (9)
Oseltamivir oral suspension 19 (3) 77 (12)
Yellow fever vaccine 13 (2) 65 (10)
Intravenous Immune Globulin IVIG (Human) 12 (2) 105 (16)
Inactivated influenza vaccine 10 (2) 60 (9)
Other shortages reported by at least one physician (typed into ‘Other’ field): Anti-bacterial agents: amoxicillin/clavulanate, ampicillin-sulbactam, 
azithromycin, capreomycin, cefazolin, ceftazidime, chloramphenicol, ciprofloxacin oral, clarithromycin tabs, clindamycin injection, clofazimine, 
dapsone, doxycycline (IV or not specified), erythromycin ophthalmic ointment, gentamicin (including preservative free), isoniazid intravenous, 
kanamycin, meropenem, metronidazole injection, metronidazole oral, nafcillin injectable, piperacillin injection, piperacillin-tazobactam injection, 
pyrimethamine, quinupristin-dalfopristin, rifampin injection, streptomycin, ticarcillin/clavulanate; Anti-viral agents: acyclovir injection, 
ganciclovir capsules; Anti-parasitic agents, anti-fungal agents, immune globulins, vaccines and others: albendazole, amphotericin – liposomal, 
ethanol for central venous catheter locks, Hemophilus influenza B vaccine, Itraconazole, Japanese encephalitis virus vaccine, measles/rubella 
vaccine, rabies immune globulin, rabies vaccine, Varicella zoster immune globulin
Diagn Microbiol Infect Dis. Author manuscript; available in PMC 2018 February 16.
